Page 149 - 2019_03-Haematologica-web

2014;127(17):3649-3658.
13. Grimm S. The ER–mitochondria interface:
Biophys Acta. 2012;1823(2):327-334.
14. Iwasawa R, Mahul‐Mellier AL, Datler C, et al. Fis1 and Bap31 bridge the mitochondria– ER interface to establish a platform for apop- tosis induction. EMBO J. 2011;30(3):556-568.
15. Namba T, Tian F, Chu K, et al. CDIP1-BAP31 complex transduces apoptotic signals from endoplasmic reticulum to mitochondria under endoplasmic reticulum stress. Cell
Rep. 2013;5(2):331-339.
16. Rosati E, Sabatini R, Rampino G, et al. Novel
targets for endoplasmic reticulum stress- induced apoptosis in B-CLL. Blood. 2010; 116(15):2713-2723.
17. Galligan JJ, Petersen DR. The human protein disulfide isomerase gene family. Hum Genomics. 2012;6:6.
18. Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today. 2014;19(3): 222-240.
19. Haefliger S, Klebig C, Schaubitzer K, et al. Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood. 2011;117(22):5931-5940.
20. Higa A, Taouji S, Lhomond S, et al. Endoplasmic reticulum stress-activated tran- scription factor ATF6α requires the disulfide isomerase PDIA5 to modulate chemoresis- tance. Mol Cell Biol. 2014;34(10):1839-1849.
21. Trivedi R, Müller G, Rathore M, et al. Anti- leukemic activity of shikonin: role of ERP57 in shikonin induced apoptosis in acute myeloid leukemia. Cell Physiol Biochem. 2016;39(2):604-616.
22. Eirich J, Braig S, Schyschka L, et al. A small molecule inhibits protein disulfide iso- merase and triggers the chemosensitization of cancer cells. Angew Chem Int ED Engl. 2014;53(47):12960-12965.
23. Xu S, Butkevich AN, Yamada R, et al.
Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide iso- merase for ovarian cancer treatment. Proc Natl Acad Sci USA. 2012;109(40):16348- 16353.
24. Vatolin S, Phillips JG, Jha BK, et al. Novel protein disulfide isomerase inhibitor with anticancer activity in multiple myeloma. Cancer Res. 2016;76(11):3340-3350.
25. Haber M, Norris MD, Kavallaris M, et al. Atypical multidrug resistance in a therapy- induced drug-resistant human leukemia cell line (LALW-2): resistance to vinca alkaloids independent of P-glycoprotein. Cancer Res. 1989;49(19):5281-5287.
26. Verrills NM, Walsh BJ, Cobon GS, et al. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alter- ations. J Biol Chem. 2003;278(46):45082- 45093.
27. Terziyska N, Alves CC, Groiss V, et al. In vivo imaging enables high resolution pre- clinical trials on patients’ leukemia cells growing in mice. PLoS One. 2012;7(12): e52798.
28. Vick B, Rothenberg M, Sandhöfer N, et al. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One. 2015; 10(3):e0120925.
29. Fukuda J, Kaneko T, Egashira M, et al. Direct measurement of CD34+ blood stem cell absolute counts by flow cytometry. Stem Cells. 1998;16(4):294-300.
30. Vomacka J, Korotkov VS, Bauer B, et al. An aromatic hydroxyamide attenuates multire- sistant Staphylococcus aureus toxin expres- sion. Chemistry. 2016;22(5):1622-1630.
31. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue): D447-452.
32. Consortium GO. Gene ontology consor- tium: going forward. Nucleic Acids Res. 2015;43(Database issue):D1049-D1056.
33. Krouglova T, Vercammen J, Engelborghs Y. Correct diffusion coefficients of proteins in fluorescence correlation spectroscopy. Application to tubulin oligomers induced by Mg2+ and Paclitaxel. Biophys J. 2004;87(4): 2635-2646.
34. Chonghaile TN, Sarosiek KA, Vo T-T, et al. Pretreatment mitochondrial priming corre- lates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059): 1129-1133.
35. Bhat TA, Chaudhary AK, Kumar S, et al. Endoplasmic reticulum-mediated unfolded protein response and mitochondrial apopto- sis in cancer. Biochim Biophys Acta Rev Cancer. 2017;1867(1):58-66.
36. Shore GC, Papa FR, Oakes SA. Signaling cell death from the endoplasmic reticulum stress response. Curr Opin Cell Biol. 2011;23 (2):143-149.
37. Simmen T, Herrera-Cruz MS. Cancer: untethering mitochondria from the ER? Front Oncol. 2017;7:105.
38. Lorkova L, Scigelova M, Arrey TN, et al. Detailed functional and proteomic charac- terization of fludarabine resistance in mantle cell lymphoma cells. PLoS One. 2015;10(8):e0135314.
39. Soriano G, Besse L, Li N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in partic- ular in redox and energy metabolism. Leukemia. 2016;30(11):2198-2207.
40. Konopleva M, Pollyea DA, Potluri J, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood. 2014;124(21):118.
41. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding envi- ronment on cancer development. Nat Rev Cancer. 2014;14(9):581-597.
the social network of cell death. Biochim
haematologica | 2019; 104(3)
PS89 - a novel option for combination therapy in acute leukemia
555